BioSpace News Archive

Immunocore Holdings plc announced that initial data from the first three patients in the first-in-human clinical trial of IMC-I109V was presented at the EASL International Liver Congress in London, UK.

Vir Biotechnology, Inc. announced new data from its robust hepatitis B virus clinical trial program, including results from an ongoing Phase 2 clinical trial of VIR-2218, results from an ongoing Phase 1 clinical trial of VIR-3434 and preclinical data evaluating both investigational compounds as monotherapy and in combination.

Antios Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative treatments for hepatitis B virus, announced new data from the Phase 2a clinical trial of ATI-2173, its lead investigational proprietary drug candidate and the only Active Site Polymerase Inhibitor Nucleotide in clinical development for HBV.

Pfizer Inc. and BioNTech SE announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent, a combination of the Pfizer-BioNTech COVID-19 Vaccine and a vaccine candidate targeting the spike protein of the Omicron BA.1 variant of concern.

Italfarmaco Group announced positive topline data from its completed Phase 3 EPIDYS trial with Givinostat, the company’s proprietary histone deacetylase inhibitor, in boys with Duchenne Muscular Dystrophy.

On June 15, 2022, Dragon Boat announced that its IND application of the innovative anti-CLDN 18.2/CD47 bi-specific antibody injection was officially accepted by National Medical Products Administration under the acceptance number CXSL2200267.

Arbutus Biopharma Corporation announced the presentation of new clinical and pre-clinical data from its proprietary compounds at the European Association for the Study of the Liver International Liver Congress™.

Ionis Pharmaceuticals, Inc., announced that GSK presented positive results from an interim analysis of the Phase 2b B-Clear clinical study of bepirovirsen, an investigational antisense medicine for the treatment of patients with chronic hepatitis B virus.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that the South African Health Products Regulatory Authority granted conditional registration to SINOVAC CoronaVac® in aged 18 and above adults, based on acceptable safety, quality, and efficacy data submitted.

Madrigal Pharmaceuticals, Inc. announced data from multiple resmetirom abstracts presented at the European Association for the Study of the Liver’s International Liver Congress, including a late-breaking presentation of data from the Phase 3 MAESTRO-NAFLD-1 study and three additional oral presentations from the resmetirom clinical development program.